APO-SALBUTAMOL HFA METERED-DOSE AEROSOL

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Koupit nyní

Aktivní složka:

SALBUTAMOL (SALBUTAMOL SULFATE)

Dostupné s:

APOTEX INC

ATC kód:

R03AC02

INN (Mezinárodní Name):

SALBUTAMOL

Dávkování:

100MCG

Léková forma:

METERED-DOSE AEROSOL

Složení:

SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG

Podání:

INHALATION

Jednotky v balení:

15G/50G

Druh předpisu:

Prescription

Terapeutické oblasti:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Přehled produktů:

Active ingredient group (AIG) number: 0108887003; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2019-08-09

Charakteristika produktu

                                _Page 1 of 25_
PRODUCT MONOGRAPH
PR
APO-SALBUTAMOL HFA
salbutamol pressurised inhalation, suspension
Mfr. Std.
100 mcg salbutamol (as salbutamol sulfate) / metered dose
Bronchodilator
(beta
2
-adrenergic agonist)
Apotex Inc.
150 Signet Drive
Toronto, Ontario
Canada M9L 1T9
Date of Revision:
June 25, 2021
Submission Control No.: 252563
_ _
_Page 2 of 25_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................
3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND
PRECAUTIONS..................................................................................
3
ADVERSE REACTIONS
...................................................................................................
6
DRUG INTERACTIONS
....................................................................................................
9
DOSAGE AND ADMINISTRATION
..............................................................................
10
OVERDOSAGE
................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 12
STORAGE AND
STABILITY..........................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 14
PART II: SCIENTIFIC INFORMATION
................................................................................
15
PHARMACEUTICAL INFORMATION
.........................................................................
15
CLINICAL TRIALS
..........
                                
                                Přečtěte si celý dokument
                                
                            

Dokumenty v jiných jazycích

Charakteristika produktu Charakteristika produktu francouzština 25-06-2021

Vyhledávejte upozornění související s tímto produktem